NACL Industries Limited has announced the allotment of 1,65,000 equity shares under its Employee Stock Option Scheme 2020 (ESOS-2020), following approval from the Nomination and Remuneration Committee on March 25, 2026. This corporate action represents the exercise of vested options by employees under the company's stock incentive program.

Share Allotment Details

The allotment encompasses 1,65,000 equity shares with a par value of ₹1 each. The shares were issued at a weighted average exercise price of ₹66.67 per share, though individual exercise prices varied for different grantees within a range of ₹50 to ₹78. The premium per share stands at ₹65.67.

Impact on Share Capital

Following this allotment, the company's equity share capital structure has been updated. The total issued shares have increased from the previous count, reflecting the dilutive effect of the employee stock option exercise.

Regulatory Compliance

The allotment has been conducted in accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company filed the original ESOS-2020 scheme statement with both BSE Limited and National Stock Exchange of India Limited on September 21, 2020. The newly issued shares carry the ISIN number INE295D01020 and will be available in demat form.

Share Characteristics

The allotted equity shares rank pari-passu with existing equity shares of the company in all respects, ensuring equal rights and privileges for all shareholders. No lock-in provisions apply to these shares, and no additional listing fees are payable for this allotment. The shares are identical to existing shares and maintain the same trading characteristics on both BSE Limited (Code: 524709) and National Stock Exchange of India Limited (Symbol: NACLIND).

NACL Industries Limited has announced a significant financial restructuring move involving the conversion of an existing inter-corporate loan into Compulsorily Convertible Debentures (CCDs) for its subsidiary company. The Board of Directors approved this transaction on March 25, 2026, as part of strategic financial management.

Transaction Overview

The company has decided to convert the outstanding inter-corporate loan of ₹51.95 crores extended to its wholly owned subsidiary, NACL Spec-Chem Limited, into CCDs. This conversion represents a financial restructuring of the company's existing exposure in the subsidiary rather than a fresh capital infusion.

CCD Structure and Terms

The conversion involves transforming the existing loan into structured debentures with specific conversion features. The outstanding inter-corporate loan aggregating to ₹51.95 crores will be converted into 5,195 Compulsorily Convertible Debentures, each carrying a face value of ₹1,00,000.

Strategic Purpose and Compliance

The primary purpose of this conversion is to restructure the financial exposure and strengthen the capital base of NACL Spec-Chem Limited. The inter-corporate loan was initially granted for a period of two years, but considering prevailing financial considerations, the company opted for this conversion structure.

The transaction qualifies as a related party transaction and will be undertaken on an arm's length basis. The CCDs are designed to be compulsorily converted into equity shares in accordance with agreed terms and applicable laws. The company has confirmed that no nominee director arrangements or potential conflicts of interest arise from this transaction.

Regulatory Framework

The conversion has been structured in compliance with applicable provisions of law, including the SEBI Listing Regulations and other statutory requirements. The company filed the necessary intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring full regulatory compliance.

This financial restructuring represents a strategic approach to optimizing the capital structure within the group while maintaining regulatory compliance and strengthening the subsidiary's financial foundation for future operations.